Śpiewak Dorota, Drzyzga Łukasz, Dorecka Mariola, Witek Katarzyna, Wyględowska-Promieńska Dorota
Department of Ophthalmology, Prof. K. Gibiński University Clinical Center, Medical University of Silesia, 40-514 Katowice, Poland.
Clinical Ophthalmology Center Okolux, 40-754 Katowice, Poland.
Pharmaceutics. 2025 Jun 30;17(7):858. doi: 10.3390/pharmaceutics17070858.
Our study aimed to assess the anatomical changes in the retina, including the assessment of the reduction of diabetic macular edema (DME) on optical coherence tomography (OCT) and the improvement of retinal microvascular parameters, defined by the reduction of nonperfusion areas on OCT angiography (OCTA) after intravitreal injections of 6 mg faricimab, an anti-VEGF drug used in the treatment of DME. The study included twenty-two patients aged between 61 and 74 years, each of whom received four loading doses of 6 mg faricimab at 1-month intervals, as described in the summary of product characteristics. Hemodynamic parameters were analyzed by OCT angiography before the first intravitreal injection of faricimab and one month after each subsequent injection. The following parameters were analyzed: non-perfusion area (NPA), superficial capillary plexus (SCP) and deep capillary plexus (DCP), outer retinal flow area (ORFA), choriocapillaris flow area (CCFA) and foveal avascular zone (FAZ). Despite differences in the magnitude of improvement and time to improvement from the start of treatment with intravitreal injections of 6 mg faricimab, reductions in DME and improvements in OCTA parameters resulted in increased retinal blood flow and better visual acuity.
我们的研究旨在评估视网膜的解剖学变化，包括通过光学相干断层扫描（OCT）评估糖尿病性黄斑水肿（DME）的减轻情况，以及通过OCT血管造影（OCTA）评估玻璃体内注射6毫克法西单抗（一种用于治疗DME的抗血管内皮生长因子药物）后视网膜微血管参数的改善情况，该参数通过减少OCTA上的无灌注区域来定义。该研究纳入了22名年龄在61至74岁之间的患者，按照产品特性摘要中的描述，每位患者每隔1个月接受4次6毫克法西单抗的负荷剂量注射。在首次玻璃体内注射法西单抗前以及随后每次注射后1个月，通过OCT血管造影分析血流动力学参数。分析了以下参数：无灌注区域（NPA）、浅表毛细血管丛（SCP）和深层毛细血管丛（DCP）、视网膜外层血流区域（ORFA）、脉络膜毛细血管血流区域（CCFA）和黄斑无血管区（FAZ）。尽管从开始玻璃体内注射6毫克法西单抗治疗起，改善程度和改善时间存在差异，但DME的减轻和OCTA参数的改善导致视网膜血流量增加和视力提高。
